Stellantis Stock Has Massive Upside, but Q3 U.S. Sales Tell a Bittersweet Story
2026-10-08 10:30
•Daniel Miller •The Motley Fool
••• ••••••• Axe Cap view
Stellantis’ Recovery Hangs on Execution Despite Bright Spots
Stellantis shows promise with strong Ram sales but Jeep struggles temper confidence ahead of its ambitious turnaround plan.
Stellantis’ Q3 results reveal a split picture. Ram’s 29% sales jump, led by the Ram 1500’s 73% surge, signals robust demand for pickups. Meanwhile, Jeep’s 20% drop highlights ongoing struggles in SUV segments crucial to the brand. The company’s $70 billion FaSTLAne 2030 plan aims to revamp product lines and boost manufacturing, betting heavily on Jeep’s revival and expanded electric vehicle offerings. Compared to rivals like Ford and GM, Stellantis trades at a fraction of their market caps, reflecting skepticism around its turnaround timeline and execution risk. For South African investors, the indirect play here is on the rand, as a weaker USD/ZAR could pressure multinational earnings and import costs, impacting sectors tied to consumer spending. The big risk: if Jeep fails to recover or global supply chain issues worsen, the stock’s deeply discounted valuation could remain grounded. Still, the potential upside for patient investors is tangible if management hits its targets. this is just our opinion and not financial advice
Watch Stellantis closely but avoid buying now; trim exposure if you hold it. Confirm sustained Jeep recovery before committing capital.
- STLA
- USD/ZAR
- Jeep brand sales remain weak
- Supply chain disruptions delay turnaround
6/10
Stellantis' Q3 U.S. sales showed mixed results as its Ram brand surged 29% with the Ram 1500 posting a 73% sales gain, while Jeep declined 20% due to slower Compass and Grand Cherokee sales. Despite the bittersweet quarter, the automaker's $70 billion FaSTLAne 2030 turnaround strategy includes expanding Jeep offerings and manufacturing capacity, positioning both brands as cornerstones for recovery. With a market cap of only $13 billion—far below competitors—patient investors may find opportunity if execution succeeds.
Our take is based on reporting first published by The Motley Fool.